FDA adds a vision warning to Zepbound shortly after Lilly begins direct sales on Hims & Hers

Eli Lilly said the U.S. Food and Drug Administration has added a “vision” warning to Zepbound, its prescription weight-loss treatment. The update lands only days after Lilly announced a commercial partnership with Hims & Hers that allows the companies to sell Zepbound and Foundayo directly through Hims & Hers, using Lilly-set self-pay pricing rather than typical pharmacy markups.

According to the report, Lilly is now selling Zepbound and Foundayo through Hims & Hers at Lilly’s own self-pay prices, joining Novo Nordisk as another GLP-1 weight-loss brand available on the platform. Hims & Hers, which sells telehealth and prescription services, is increasingly positioned as a direct-to-consumer channel for obesity and weight-management medications in addition to traditional pharmacy distribution.

The report also attributes recent performance changes to Lilly’s broader push into direct sales channels. It says Zepbound volume rose 53% in the third quarter, while realized prices fell 15%. “Realized price” generally refers to the price the manufacturer effectively receives after rebates, discounts, and other adjustments, so the combination suggests growth in units but pressure on net pricing.

The new FDA warning indicates that safety labeling for Zepbound continues to evolve. FDA labeling updates can affect prescriber behavior and, in some cases, patient perceptions, particularly when warnings relate to specific side effects. The report does not provide the exact language of the warning, what specific vision symptoms are described, or whether any new clinical data prompted the change.

Lilly’s timing matters commercially because it coincides with its decision to expand Zepbound’s access footprint through Hims & Hers. Direct-to-consumer platforms can increase speed to market and simplify purchase pathways for patients, but they also make the product’s labeling and safety communications more visible in marketing and telehealth workflows.

More broadly, weight-loss drug manufacturers have been racing to secure distribution relationships as the category matures. Telehealth networks and e-commerce-like prescribing journeys have become a battleground for patient acquisition, ongoing refills, and payer-neutral pricing strategies such as “self-pay” programs.

The report does not disclose whether Lilly plans additional education campaigns for clinicians or patients in response to the new vision warning, nor does it specify whether Zepbound is being relabeled across all channels simultaneously. It also does not clarify whether the “vision” warning changes clinical eligibility, monitoring requirements, or treatment interruptions in practice.

Investors and observers will be watching for follow-through: whether FDA labeling changes influence prescribing patterns, whether direct-channel growth offsets any net price pressure, and whether other platforms in the obesity telehealth market add similar safety-forward communications around Zepbound. Any further FDA updates, or clarifying communications from Lilly to prescribers and patients, would likely be a near-term focus for the market.